Literature DB >> 15799869

A kit for labeling of [188Re] human serum albumin microspheres for therapeutic use in nuclear medicine.

Gerd Wunderlich1, Antje Drews, Jörg Kotzerke.   

Abstract

Intra-arterial infusion of labeled particles is an effective method for local endoradiotherapy of tumors. In this study, we present an efficient method of radiolabeling biodegradable human serum albumin (HSA) microspheres with the short-lived beta-emitter 188Re using a simple and reliable kit. Up to now, it was not possible to label particles with more than 85-90% efficiency. Under optimized reaction conditions, we achieved nearly 100% uptake of 188Re. Using the proposed kit, we added tartrate solution and increased the pH from 2 to 4-5 after 1 h reaction time at 95 degrees C. The 188Re binding to the particles was found to be stable in vitro.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15799869     DOI: 10.1016/j.apradiso.2005.01.001

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  4 in total

1.  Radiobiological considerations for radioembolization with 188Re-microspheres.

Authors:  Liane Oehme; Jörg Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-19       Impact factor: 9.236

Review 2.  Transarterial Radioembolization Agents: a Review of the Radionuclide Agents and the Carriers.

Authors:  Aysheh Alrfooh; Aditi Patel; Sandeep Laroia
Journal:  Nucl Med Mol Imaging       Date:  2021-07-13

3.  Initial study of radiological and clinical efficacy radioembolization using 188Re-human serum albumin (HSA) microspheres in patients with progressive, unresectable primary or secondary liver cancers.

Authors:  Mirosław L Nowicki; Jarosław B Cwikla; Artur J Sankowski; Sergey Shcherbinin; Josh Grimmes; Anna Celler; John R Buscombe; Andrzej Bator; Maciej Pech; Renata Mikołajczak; Dariusz Pawlak
Journal:  Med Sci Monit       Date:  2014-08-02

Review 4.  Transarterial Radioembolization (TARE) Agents beyond 90Y-Microspheres.

Authors:  C Bouvry; X Palard; J Edeline; V Ardisson; P Loyer; E Garin; N Lepareur
Journal:  Biomed Res Int       Date:  2018-12-31       Impact factor: 3.246

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.